Menu
Recruiting NCT07321353

Survivors Journey+

No phase Interventional Pediatric Brain Tumor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Survivor's Journey+.
Who it may be relevant to
Registry conditions: Pediatric Brain Tumor. Basic parameters: 15 years — 25 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Online Problem-Solving Intervention for Brain Tumor Survivors: A Two-site, Two-arm Pilot Randomized Controlled Trial

Overview

The main goal of this pilot randomized controlled trial is to learn if an online program called "Survivors Journey" (SJ+) can help teens and young adults, ages 15-25, who are Pediatric Brain Tumor Survivors (PBTS), and their caregivers, manage everyday challenges better by using skills like problem-solving and coping skills. The main questions it aims to answer are: * Is the SJ+ program rated as feasible (\>50% enrollment rate and \>75% retention rate) and acceptable (\>80% satisfaction rate) by PBTS and their caregivers? * Does the SJ+ program have better outcomes in improving PBTS and caregiver wellbeing in comparison to an internet resource comparison (IRB) made for PBTS and their families? Participants will be randomized into two groups: one group will be given access to the online SJ+ program and receive weekly online coaching sessions, and the other group will be given access to an IRC. Outcomes will be assessed at baseline, treatment completion (\~ 3 months post-baseline), and at follow-up six months post-baseline. These outcomes include quality of life, internalizing symptoms, performance-based executive function skills, depression, and family impact.

Detailed description

Pediatric brain tumor survivors (PBTS) experience worse outcomes compared to other survivors or healthy adolescents and young adults. This includes quality of life (QoL), neurocognitive late effects, declines in IQ, executive functioning (EF), and social problem-solving skills. As adolescents navigate academic and social challenges, neurocognitive late effects place PBTS at elevated risk for impaired functioning during this critical transition. Equipping PBTS and their caregivers with a set of skills to manage stress, solve problems, and address neurocognitive and social challenges may promote better outcomes and prevent further declines in QoL. Prior research has targeted the survivor or caregiver in isolation, and not as family-centered treatment.

PBTS assume the largest burden of late effects from childhood cancer, with few effective solutions to address their lifelong challenges. Caregivers and families also experience stress and burden that can impact everyday functioning. Survivor's Journey Plus (SJ+) addresses this urgent need by offering a developmentally tailored, family-centered approach to improving social problem-solving, emotion-regulation, and metacognitive skills in PBTS, while offering strategies to reduce caregiver depression and family impact.

Our overarching objectives are to: 1) to refine the existing program based on feedback from patient advocates and establish usability and accessibility; 2) examine the efficacy of SJ+ in improving global QoL, internalizing symptoms, and EF skills in adolescent/emerging adult PBTS; and 3) examine the efficacy of SJ+ in reducing caregiver depression and family impact. Importantly, we will consider improvements in both patient-reported and performance-based outcomes. We will conduct a two-site, two-arm pilot RCT (n = 72) comparing SJ+ to an internet resource comparison (IRC) with outcomes assessed at baseline, treatment completion (\~ 3 months post-baseline), and 6 months post-baseline.

SJ+ provides training in contextualized metacognitive strategies and communication skills to address common challenges (e.g., working memory, attention/planning, social communication) in the context of a broader social problem-solving framework. It is predicated on more than two decades of research with pediatric brain injury survivors, demonstrating its feasibility, acceptability, and efficacy among adolescents and young adults.

Interventions

  • Behavioral Survivor's Journey+
    Our overarching objectives are to: 1) to refine the existing program based on feedback from patient advocates and establish usability and accessibility; 2) examine the efficacy of SJ+ in improving global QoL, internalizing symptoms, and EF skills in adolescent/emerging adult PBTS; and 3) examine the efficacy of SJ+ in reducing caregiver depression and family impact.

Primary outcome measures

  • Pediatric Quality of Life Inventory Total Scale Score change [Time frame: From baseline to 6 months post-baseline]
  • Goal Attainment Scaling [Time frame: From baseline to 6 months post-baseline.]
Secondary outcome measures (5)
  • Behavior Rating Inventory of Executive Function, Second Edition T Scores change [Time frame: From baseline to 6 months post-baseline]
  • Behavior Rating Inventory of Executive Function, Second Edition-Adult Version T Scores change [Time frame: From baseline to 6 months post-baseline]
  • Patient-Reported Outcomes Measurement Information System change [Time frame: From baseline to 6 months post-baseline]
  • Hospital Anxiety and Depression Scale change [Time frame: From baseline to 6 months post-baseline]
  • Strength & Difficulties Questionnaire change [Time frame: From baseline to 6 months post-baseline]

Eligibility criteria

Inclusion criteria

  • a diagnosis of a pediatric intracranial tumor
  • tumor-directed treatment completed > 12 months ago (treatment included: surgery, radiation, or chemotherapy)
  • lives with parent/guardian(s)
  • language: English must be the primary spoken language in the home

Exclusion criteria

  • history of tuberous sclerosis or neurofibromatosis
  • treatment < 12 months ago and/or treatment did not include surgery, radiation, or chemotherapy
  • history of psychiatric hospitalization
  • resides outside of the family home
  • history of autism, reactive attachment disorder, psychosis, or other psychiatric diagnoses/conditions associated with significant risk of harm to self or others per caregiver
  • English is not the primary language spoken in the home

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 2 centers
  • Cincinnati Children's Hospital Medical Center — Cincinnati
  • Nationwide Children's Hospital — Columbus

Identifiers

NCT: NCT07321353 · 2024-0546 · HT9425-24-1-0746

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗